Just when we thought we could end the week without any more insanity, everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), issued a brand new, utterly ridiculous, press release (here). No doubt desperate to maintain a $4 bid price for that ever-elusive “uplisting” (Pro Tip: any company that talks about UPlisting is a scam, plain and simple. Cytodyn is currently UNlisted, it is applying for an INITIAL listing). Let’s take a look at what BS The NaDDir* is slinging this morning:

Interesting, seeing as though the company couldn’t even get its BLA accepted for review in the USA. Exactly what does “seeking approval” entail? Read past the headine:

VANCOUVER, Washington, Aug. 06, 2020 (GLOBE NEWSWIRE) —  CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company, announced today it will submit requests for pre-submission meetings (equivalent to pre-BLA meeting in U.S.) in the U.K. for leronlimab as an HIV treatment in combination with HAART for highly treatment experienced HIV patients (350 mg dose, self-injectable, subcutaneous ), as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate symptoms (Phase 2 – CD10).

In The NaDDir*’s world (*spelled thusly for a double dose of that sweet sweet stock pimpin’) seeking approval actually means merely submitting a request for a meeting!

And the subject of that meeting is quite interesting, the 350mg dose of leronlimab for HIV combination therapy. The company submitted the now infamous botched BLA for that same indication in the USA, but for the 700mg dose. After a series of miscues by Cytodyn, the FDA, as you may recall, sent the company a humiliating RTF (Refuse To File) letter, telling them to go back to the drawing board.

Any why even bother with the 350mg dose? By the company’s own admission it doesn’t work very well, with only a 70% response rate.

Notice anything else about that chart? When the middle dose outperforms the low and the high dose, what should that tell you?

One last tidbit, one dose is actually 2 injections. Good luck with that.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.